These results suggest that IHCH9033 can alter the fate of FLT3i-resistant AML cells on FLT3 inhibition, exhibiting significant potency against these cells and strong synergy with the FLT3i quizartinib characterized by increased levels of DNA damage and apoptosis and decreased levels of DNA repair proteins. Here, XRCC6P5 is linked to acute myeloid leukemia.